Pfizer, BioNTech start COVID-flu combination vaccine study

Pfizer/BioNTech begin phase 1 of COVID-19/influenza combo

BioNTech and Pfizer have announced that they are initiating a phase 1 study to evaluate a single dose mRNA-based combination vaccine candidate against influenza and COVID-19

Pfizer, BioNTech report bivalent Covid-19 booster more protective than original vaccine

Neutralizing antibodies targeting Omicron BA.4/BA.5 viruses were four-fold higher in people aged 55 and older who received the bivalent booster.

Pfizer-BioNTech to test combined COVID, influenza vaccine

Frankfurt: Pfizer-BioNTech said they will test a combined coronavirus and influenza vaccine, which could potentially pave the way for better inoculation uptake for both illnesses.The companies said in...

Pfizer and BioNTech combination COVID-19 and flu vaccine could be on the horizon

Pfizer and BioNTech have announced the launch of a phase 1 trial for a dual-purpose mRNA-based vaccine to tackle both influenza and COVID-19

Pfizer, BioNTech launch phase 1 trial on combined COVID-19 and flu vaccine

Pfizer and BioNTech announced Thursday that they have started a phase 1 trial on a combination COVID-19 and influenza vaccine.

Pfizer testing combined COVID, flu vaccine

Pfizer and BioNTech have launched a phase 1 trial for an mRNA-based vaccine that would target both COVID-19 and the influenza virus. According to BioNTech, the vaccine candidate is a combination of Pfizer’s flu vaccine candidate, which is in phase 3 clinical development, and the company’s bivalent omicron-specific coronavirus vaccine dose. The study includes 180…